<DOC>
	<DOC>NCT01251653</DOC>
	<brief_summary>To establish the maximum tolerated dose (MTD) of oral afatinib (BIBW2992) given in combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors. To assess the safety of the combination. To investigate the PK characteristics of docetaxel or gemcitabine and of oral afatinib (BIBW2992) in the tested treatment schedule. To assess antitumor activity.</brief_summary>
	<brief_title>A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criteria: 1. histologically or cytologically confirmed diagnosis of any advanced or metastatic relapsed or refractory solid tumor. Exclusion criteria: 1. Active brain metastases 2. Patients with known preexisting interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>